NEW YORK and BOSTON, Sept. 12, 2017 -- Mizuho Americas will host a Biotechnology Conference on September 19th at the Langham Hotel in Boston. The event will feature opportunities for institutional investors to meet senior executives from neurology companies that are pioneering advancements in gene therapy, pharmaceuticals and diagnostics.
Salim Syed, Managing Director and Head of Biotechnology Research for Mizuho Americas, will moderate three panel discussions with renowned research doctors discussing companies developing advancements in multiple sclerosis treatments, migraine relief through calcitonin gene-related peptide therapies and scientific strides in the prevention and treatment of Alzheimer’s disease.
“It is a dynamic time of growth and discovery for many biotech companies,” said Matt DeSalvo, Head of Equities, Mizuho Americas. “We have assembled top executives at firms who are experts in this sector and are creating some of the most exciting breakthroughs of our time.”
Institutional investors and C-suite executives will gain valuable insight and better understand the drivers and influences that will shape the biotech industry. Attendees will have an opportunity to meet with senior executives of these biotech companies. For more information, please contact Mizuho Americas Corporate Access at [email protected].
The Biotechnology Conference is the latest in a series of investor conferences hosted by Mizuho Americas that have taken place this year. The inaugural Global Mizuho Investor Conference (MIC), NY was held in November 2016 and will take place this year on December 4-5, 2017. The conference brings Mizuho’s clients together with key decision-makers and executives across the energy, financials, healthcare, industrials, REITs, TMT, consumer and utilities sectors in a one-on-one setting.
About Mizuho Americas
Mizuho Americas is a leading financial institution comprising several legal entities, which together offer clients corporate and investment banking, financing, securities, treasury services, asset management, research and more. With professionals in offices throughout the US, Canada, Mexico, Brazil and Chile, Mizuho’s operations in the Americas connect a broad client base of major corporations, financial institutions and public sector groups to local markets and a vast global network. Learn more at www.mizuhoamericas.com.
Mizuho Americas is an integral part of the Japan-based Mizuho Financial Group, Inc. (NYSE:MFG). Mizuho Financial Group is one of the largest financial institutions in the world, offering comprehensive financial and strategic services including private banking and venture capital through its subsidiaries. The group has over 900 offices and 56,000 employees worldwide in nearly 40 countries throughout the Americas, EMEA, and Asia. At the end of 2016, its total assets were $1.8 trillion. Learn more about Mizuho Financial Group at https://www.mizuho-fg.com
For further inquiries, please contact:
Jim Gorman
Director, Media Relations, Mizuho Americas
+1 212 282 3867; [email protected]
P.J. Kinsella
Paragon Public Relations
+1 646 558 6226; [email protected]


SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 



